原发性胰样肝癌1例报告并文献复习

Journal of Cancer Research and Practice Pub Date : 2023-01-01 DOI:10.4103/ejcrp.ejcrp-d-22-00037

Hsiang-Fong Kao, Tyng-Wei Yang

{"title":"原发性胰样肝癌1例报告并文献复习","authors":"Hsiang-Fong Kao, Tyng-Wei Yang","doi":"10.4103/ejcrp.ejcrp-d-22-00037","DOIUrl":null,"url":null,"abstract":"Hepatoid carcinoma is a rare primary malignancy in the pancreas. We report a case with a long indolent course of primary pancreatic hepatoid carcinoma (PHC) before curative surgery, with an estimated doubling time of 429 days. After surgery, the patient took adjuvant TS-1 (tegafur, gimeracil, and oteracil). They did not have recurrence or metastases 9 months after surgery. We reported their pathological features. We review PHC’s clinical features, pathological diagnosis, and reported treatment experiences.","PeriodicalId":31219,"journal":{"name":"Journal of Cancer Research and Practice","volume":"275 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Primary pancreatic hepatoid carcinoma: A case report and literature review\",\"authors\":\"Hsiang-Fong Kao, Tyng-Wei Yang\",\"doi\":\"10.4103/ejcrp.ejcrp-d-22-00037\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Hepatoid carcinoma is a rare primary malignancy in the pancreas. We report a case with a long indolent course of primary pancreatic hepatoid carcinoma (PHC) before curative surgery, with an estimated doubling time of 429 days. After surgery, the patient took adjuvant TS-1 (tegafur, gimeracil, and oteracil). They did not have recurrence or metastases 9 months after surgery. We reported their pathological features. We review PHC’s clinical features, pathological diagnosis, and reported treatment experiences.\",\"PeriodicalId\":31219,\"journal\":{\"name\":\"Journal of Cancer Research and Practice\",\"volume\":\"275 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Cancer Research and Practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/ejcrp.ejcrp-d-22-00037\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer Research and Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/ejcrp.ejcrp-d-22-00037","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

肝样癌是胰腺中一种罕见的原发性恶性肿瘤。我们报告一例原发性胰岛类肝癌(PHC)在根治性手术前的长期无痛病程，估计翻倍时间为429天。手术后，患者服用辅助治疗TS-1(替加富、吉美拉西和奥他拉西)。术后9个月无复发或转移。我们报道了他们的病理特征。我们回顾PHC的临床特征，病理诊断和报道的治疗经验。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Primary pancreatic hepatoid carcinoma: A case report and literature review

Hepatoid carcinoma is a rare primary malignancy in the pancreas. We report a case with a long indolent course of primary pancreatic hepatoid carcinoma (PHC) before curative surgery, with an estimated doubling time of 429 days. After surgery, the patient took adjuvant TS-1 (tegafur, gimeracil, and oteracil). They did not have recurrence or metastases 9 months after surgery. We reported their pathological features. We review PHC’s clinical features, pathological diagnosis, and reported treatment experiences.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Cancer Research and Practice

自引率

0.00%

发文量

审稿时长

24 weeks

期刊介绍： JCRP aims to provide an exchange forum for the cancer researchers and practitioners to publish their timely findings in oncologic disciplines. The scope of the Journal covers basic, translational and clinical research, Cancer Biology, Cancer Immunotherapy, Hemato-oncology, Digestive cancer, Urinary tumor, Germ cell tumor, Breast cancer, Lung cancer, Head and Neck Cancer in a vast range of cancer related topics. The Journal also seeks to enhance and advance the cancer care standards in order to provide cancer patients the best care during the treatments.